R

    Replimune Group Inc (REPL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.30
    -0.20 (-1.29%)

    Market Cap: $1.46B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    42%(14/33)
    Avg Surprise
    -24.61%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.83
    Range$-0.85 - $-0.82
    2 analysts
    EPS Revisions
    1
    0
    7d
    No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.54+35.2%
    60d ago$-0.54+35.8%
    30d ago$-0.56+33.4%
    7d ago$0.00+100.0%
    Current$-0.83
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    Dec 31, 2026
    EPS Consensus$-0.79
    Range$-0.83 - $-0.75
    2 analysts
    EPS Revisions
    2
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.52+33.9%
    60d ago$-0.49+38.0%
    30d ago$-0.44+44.3%
    7d ago$0.00+100.0%
    Current$-0.79
    Revenue Consensus
    $7M
    Range$0 - $21M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 27EST
    		-$-0.58---
    Dec 26EST
    		-$-0.79---
    Sep 26EST
    		-$-0.83---
    Jun 26
    		$-0.72$-0.72+0.00%Beat+24.2%
    Mar 26
    		$-0.76$-0.73-4.11%Miss+7.3%
    Dec 25
    		$-0.77$-0.82+6.10%Beat+2.5%
    Sep 25
    		$-0.90$-0.79-13.92%Miss-32.4%
    Jun 25
    		$-0.95$-0.83-14.46%Miss-21.8%
    Mar 25
    		$-0.82$-0.69-18.84%Miss-228.0%
    Dec 24
    		$-0.79$-0.72-9.72%Miss-2.6%
    Sep 24
    		$-0.68$-0.74+8.11%Beat+24.4%
    Jun 24
    		$-0.78$-0.83+6.02%Beat-4.0%
    Mar 24
    		$-0.25N/A+68.75%Beat+66.2%
    Dec 23
    		$-0.77$-0.93+17.20%Beat-11.6%
    Sep 23
    		$-0.90$-0.89-1.12%Miss-13.9%
    Jun 23
    		$-0.75$-0.84+10.71%Beat+3.8%
    Mar 23
    		$-0.74$-0.66-12.12%Miss-23.3%
    Dec 22
    		$-0.69$-0.74+6.76%Beat-21.1%
    Sep 22
    		$-0.79$-0.76-3.95%Miss-41.1%
    Jun 22
    		$-0.78$-0.56-39.29%Miss-47.2%
    Mar 22
    		$-0.60$-0.60+0.00%Beat-46.3%
    Dec 21
    		$-0.57$-0.57+0.00%Beat-35.7%
    Sep 21
    		$-0.56$-0.52-7.69%Miss-21.7%
    Jun 21
    		$-0.53$-0.42-26.19%Miss-20.5%
    Mar 21
    		$-0.41$-0.38-7.89%Miss+0.0%
    Dec 20
    		$-0.42$-0.41-2.44%Miss+8.7%
    Sep 20
    		$-0.46$-0.44-4.55%Miss-31.4%
    Jun 20
    		$-0.44$-0.43-2.33%Miss-46.7%
    Mar 20
    		$-0.41$-0.45+8.89%Beat-173.3%
    Dec 19
    		$-0.46$-0.36-27.78%Miss-91.7%
    Sep 19
    		$-0.35$-0.34-2.94%Miss-34.6%
    Jun 19
    		$-0.30$-0.31+3.23%Beat+85.1%
    Mar 19
    		$-0.15N/A+62.50%Beat+64.3%
    Dec 18
    		$-0.24$-0.25+4.00%Beat-
    Sep 18
    		$-0.26$-0.19-36.84%Miss-
    Jun 18
    		$-2.02$-0.23-778.26%Miss-
    Mar 18
    		$-0.42$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-4.86EV/EBITDA-0.24x
    Price/FCF-5.28xFCF Yield-18.93%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-134.30%ROIC-157.13%
    Financial Health
    Debt/Equity0.80xInterest Coverage-30.00x
    Current Ratio5.23xQuick Ratio5.23x
    Trading Statistics
    Beta0.90Avg Volume4.50M
    52-Week High$16.1552-Week Low$1.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$15.20
    SMA 20$14.40
    SMA 50$11.91
    SMA 200$8.46
    EMA 10$15.09
    EMA 20$14.17
    EMA 50$12.09
    EMA 200$9.11

    MACD

    Line: 1.26Signal: 1.29Hist: -0.03

    ADX

    ADX: 34.5+DI: 31.4-DI: 17.6

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down8.0
    PSAR$16.15

    Bollinger Bands

    Upper Band$17.03
    Lower Band$11.77
    %B Position3657%(Upper)
    Band Width0.67

    RSI (14-Day)

    Neutral
    61.4

    Momentum Oscillators

    Stoch %K76.7
    Stoch %D85.9
    Williams %R-33.6
    ROC (10d)4.6%
    Momentum0.67
    CCI (20d)58.8
    MFI (14d)59.5

    Volatility Measures

    ATR (14d)$1.14(7.5%)
    StdDev (20d)1.32
    Hist Vol87.5%(High)

    Volume Flow

    VWAP$15.24
    OBV324.2M
    AD Line24.2M
    CMF (20d)0.053

    Volume Metrics

    Avg Vol (20d)4.1M
    Vol Ratio0.4x(Low)
    VWMA (20d)$13.98

    Pivot Points

    R3$16.25
    R2$16.06
    R1$15.78
    Pivot Point$15.59
    S1$15.31
    S2$15.12
    S3$14.84

    Advanced Oscillators

    TSI26.34
    Ultimate Osc64.6
    KST582.29

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$1.47M$0$0$0$4.04M$0$0
    Cost of Revenue$0N/A$0$0$0$848,000$0$0$0$655,000$0$0
    Gross Profit$0N/A$0$0$0$-848,000$0$0$0$3.39M$0$0
    Operating Expenses$68.25M$73.34M$71.87M$84.29M$90.42M$79.70M$65.64M$58.92M$57.37M$56.83M$56.54M$63.83M
    R&D$49.28M$52.32M$53.14M$57.88M$57.84M$55.40M$47.63M$43.45M$42.97M$40.66M$42.85M$49.10M
    SG&A$18.97M$21.01M$18.73M$26.41M$32.58M$24.30M$18.02M$15.47M$14.39M$16.18M$13.69M$14.73M
    Operating Income$-68,247,000$-73,338,000$-71,868,000$-84,291,000$-90,422,000$-79,325,000$-66,019,000$-58,916,000$-57,367,000$-58,754,000$-56,540,000$-63,831,000
    Interest Income$1.96M$2.37M$2.85M$3.70M$4.71M$5.88M$5.14M$5.39M$4.71M$5.43M$5.69M$6.05M
    Interest Expense$3.09M$2.88M$1.98M$2.01M$2.00M$1.99M$1.98M$1.97M$1.96M$1.95M$1.55M$1.50M
    Income Before Tax$-69,766,000$-73,457,000$-71,241,000$-83,100,000$-86,693,000$-74,237,000$-65,765,000$-53,055,000$-53,772,000$-55,140,000$-50,647,000$-60,245,000
    Income Tax Expense$0$0$-311,000$0$0$0$575,000$0$0$-65,000$473,000$-201,000
    Net Income$-69,766,000$-73,217,000$-70,930,000$-83,100,000$-86,693,000$-74,130,000$-66,340,000$-53,055,000$-53,772,000$-55,075,000$-51,120,000$-60,044,000
    EBITDA$-67,207,000$-71,886,000$-70,786,000$-85,439,000$-89,270,000$-78,743,000$-69,320,000$-57,206,000$-57,804,000$-62,649,000$-57,162,000$-66,511,000
    EBIT$-68,639,000$-72,949,000$-72,107,000$-84,790,000$-89,411,000$-77,753,000$-69,300,000$-56,480,000$-56,523,000$-60,543,000$-54,781,000$-64,797,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about REPL

    News

    REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

    Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) and its officers. The lawsuit alleges that Replimune made false or misleading statements regarding deficiencies in its BLA submission to the FDA. Investors who purchased Replimune securities between October 20, 2025, and April 10, 2026, are encouraged to join the lawsuit, with a deadline of October 5, 2026, to request lead plaintiff status.

    ACCESS Newswire•8/26/26•
    Bearish

    Investors can lead lawsuit over Replimune's alleged securities fraud and misleading FDA data disclosures

    Glancy Prongay Wolke & Rotter LLP has initiated a class action lawsuit against Replimune Group, Inc., accusing the company of securities fraud. The lawsuit alleges that Replimune made false statements and concealed crucial information regarding FDA study design issues and early trial data, misleading investors about its prospects and causing financial losses. Investors impacted by these alleged actions have until October 5, 2026, to seek lead plaintiff status in the lawsuit.

    Pluang•8/25/26•
    Bearish

    Replimune Group, Inc. (REPL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

    Glancy Prongay Wolke & Rotter LLP has announced that investors who suffered losses in Replimune Group, Inc. (REPL) have an opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that Replimune Group, Inc. made materially false or misleading statements and failed to disclose critical information regarding its Biologics License Application (BLA) for its drug RP1, specifically concerning unaddressed FDA study design concerns and the submission of insufficient data. Investors have until October 5, 2026, to move the Court to serve as lead plaintiff.

    PR Newswire•8/25/26•
    Bearish

    REPL Stockholders Have Rights – If You Lost Money Investing

    Robbins LLP has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune misled investors regarding the efficacy of its lead product candidate RP1, failing to address FDA concerns in its Biologics License Application (BLA). This led to a significant drop in the company's stock price after the FDA rejected the BLA.

    GlobeNewswire•8/25/26•
    Bearish

    REPL Stockholders Have Rights – If You Lost Money Investing

    Robbins LLP, a shareholder rights law firm, has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune misled investors regarding the efficacy of its lead product candidate, RP1, which led to a significant stock drop after the FDA rejected its Biologics License Application. Investors who suffered losses are encouraged to contact Robbins LLP by October 5, 2026, to learn about their legal rights and potentially become lead plaintiff.

    GlobeNewswire•8/25/26•
    Bearish

    Frequently Asked Questions About REPL

    Does REPL pay dividends?
    Replimune Group Inc (REPL) does not currently pay a regular dividend.
    What is REPL's market cap?
    Replimune Group Inc (REPL) has a market capitalization of $1.46B with a current stock price of $15.30.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In